» Articles » PMID: 37672206

A Genetic Profiling Guideline to Support Diagnosis and Clinical Management of Lymphomas

Abstract

The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas. Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a "next-generation sequencing" guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma entities with diagnostic, prognostic, and predictive potential and proposes targeted sequencing panels to detect mutations and copy-number alterations for B- and NK/T-cell lymphomas.

Citing Articles

Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients.

Tanabe A, Ndzinu J, Sahara H Int J Mol Sci. 2024; 25(23).

PMID: 39684518 PMC: 11640839. DOI: 10.3390/ijms252312807.


Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

Alfaifi A, Bahashwan S, Alsaadi M, Ageel A, Ahmed H, Fatima K Adv Hematol. 2024; 2024:5948170.

PMID: 39563886 PMC: 11576080. DOI: 10.1155/2024/5948170.


Pathogenic Variants Associated with Epigenetic Control and the NOTCH Pathway Are Frequent in Classic Hodgkin Lymphoma.

Santisteban-Espejo A, Bernal-Florindo I, Montero-Pavon P, Perez-Requena J, Atienza-Cuevas L, Fernandez-Valle M Int J Mol Sci. 2024; 25(5).

PMID: 38473705 PMC: 10931057. DOI: 10.3390/ijms25052457.


Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.

Huang Z, Fu Y, Yang H, Zhou Y, Shi M, Li Q Mol Cancer. 2024; 23(1):36.

PMID: 38365716 PMC: 10874034. DOI: 10.1186/s12943-024-01947-7.

References
1.
Crombie J, Davids M . IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017; 92(12):1393-1397. PMC: 5675754. DOI: 10.1002/ajh.24808. View

2.
Mata E, Diaz-Lopez A, Martin-Moreno A, Sanchez-Beato M, Varela I, Mestre M . Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget. 2018; 8(67):111386-111395. PMC: 5762329. DOI: 10.18632/oncotarget.22799. View

3.
Sha C, Barrans S, Cucco F, Bentley M, Care M, Cummin T . Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol. 2018; 37(3):202-212. PMC: 6338391. DOI: 10.1200/JCO.18.01314. View

4.
Thieblemont C . Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):371-378. PMC: 6142593. DOI: 10.1182/asheducation-2017.1.371. View

5.
Jain P, Wang M . Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022; 97(5):638-656. DOI: 10.1002/ajh.26523. View